RecruitingNot a traditional drug phaseinterventionalRules rewrite

Not a traditional drug phase: testing Lidocaine 2% and Methylprednisolone 80 mg for Migraine Disorders

Q: Is NCT07568496 still recruiting?

The sponsor posted status “Recruiting” on ClinicalTrials.gov at last ingest. Sites can pause independently. Confirm with the official record and the listed contact.

Q: What phase is NCT07568496?

Not a traditional drug phase. Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

Q: Can PlainTrials tell me if I qualify for NCT07568496?

No. The inclusion and exclusion lists on this page are readable extracts of the public eligibility block. Only the study team can screen you.

Migraine is among the leading causes of disability worldwide. Inappropriate use of acute medications in the setting of primary headache, particularly migraine can result in a debilitating condition known as medication overuse headache (MOH).

Official registry: https://clinicaltrials.gov/study/NCT07568496 · Mahidol University · enrollment listed as 130

What this phase means

This study does not use the classic phase 1–4 drug ladder. It may be a device, a behavior program, a surgery timing study, or an early feasibility test.

Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

What the registry says happens

If you join, the listed intervention(s) are Lidocaine 2% and Methylprednisolone 80 mg, or Placebo. The registry lists allocation as randomized. Migraine is among the leading causes of disability worldwide.

They plan to enroll about 130 people at 3 sites. Taking part typically means taking a study drug (or dummy pill) plus check-ins.

Official title (unrewritten)

Greater Occipital Nerve Block for Migraine With Medication Overuse Headache

Interventions: Lidocaine 2% and Methylprednisolone 80 mg, Placebo

Primary outcome (registry wording): Percentage of patients with Medication Overuse Headache (MOH)

Who it is for (from inclusion criteria)

Ages 18 Years to 80 Years
Patients who have a diagnosis of migraine with medication overuse headache according to ICHD-3 criteria confirmed by a neurologist
Female patients will be screened for pregnancy planning and married female patients must undergo a urine pregnancy test

Who the registry excludes

Patients who have other types of headache disorders other than migraine
Patients who have a previous history of allergy to corticosteroid or lidocaine
Patients who had previous skull surgery
Patients with a history of uncontrolled depression, or psychosis
Patients who get or plan to get CGRP-targeted therapies or botulinum toxin injection
Patients with an increased risk of bleeding or underlying bleeding disorders

Public study contact (from the registry)

Pannathat Soontrapa, M.D.

+6690-568-6388

pannathat.soo@mahidol.ac.th

Published on ClinicalTrials.gov. Contact them as a possible participant. They decide eligibility.

Sites listed on ClinicalTrials.gov

3 listed

Faculty of Medicine Siriraj Hospital, Mahidol University — Bangkok, Bangkok, Thailand (recruiting)
Faculty of Medicine, Prince of Songkla University — Hat Yai, Changwat Songkhla, Thailand (recruiting)
Faculty of Medicine, Chiang Mai University — Chiang Mai, Chiang Mai, Thailand (not_yet_recruiting)

Related recruiting trials in this snapshot

RecruitingPhase 3Birmingham, Alabama

Phase 3: testing Rimegepant/BHV3000 for Pediatric Migraine

This study wants to test the safety and how well it works of BHV-3000 versus dummy treatment (placebo) in the acute treatment of moderate or severe migraine in children and adolescents.

NCT04649242 · Official ClinicalTrials.gov record · Pfizer

RecruitingPhase 3Scottsdale, Arizona

Phase 3: testing Rimegepant (PF-07899801) for Acute Treatment of Migraine

This study wants to test the long-term safety of rimegepant in the acute treatment of migraine in children and adolescents (≥ 6 to \< 18 years of age).

NCT04743141 · Official ClinicalTrials.gov record · Pfizer

RecruitingPhase 3New Haven, Connecticut

Phase 3: testing Eptinezumab for Chronic Migraine in Children

To find out if eptinezumab is better than dummy treatment (placebo) (normal saline solution) in lowering the number of days with migraine in young people ages 12 to 17 with chronic migraine.

NCT04965675 · Official ClinicalTrials.gov record · H. Lundbeck A/S

FAQ about this NCT record

Is NCT07568496 still recruiting?

The sponsor posted status “Recruiting” on ClinicalTrials.gov at last ingest. Sites can pause independently. Confirm with the official record and the listed contact.

What phase is NCT07568496?

Not a traditional drug phase. Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

Can PlainTrials tell me if I qualify for NCT07568496?

No. The inclusion and exclusion lists on this page are readable extracts of the public eligibility block. Only the study team can screen you.

How to read a ClinicalTrials.gov record · Questions to ask the coordinator · Glossary